Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Albanesi

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 2012
Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanomaMarcello Albanesi, David A Mancardi, Lynn E Macdonald, et al.
Respiratory Medicine|November 29, 2019
Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective studyDanilo Di Bona, Stefania Magistà, Lucia Masciopinto, et al.
European Journal of Immunology|August 22, 2014
Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastasesLeila Ben Merzoug, Solenne Marie, Naoko Satoh-Takayama, et al.
Acta Dermatovenerologica Croatica : ADC|September 6, 2017
Mast Cell Disorders, Melanoma and Pancreatic Carcinoma: From a Clinical Observation to a Brief Review of the LiteratureGiovanni Paolino, Maria Belmonte, Stefania Trasarti, et al.
The Journal of Allergy and Clinical Immunology. Global|March 4, 2026
Response to venom immunotherapy: Exploratory retrospective machine learning clustering analysisStefano Palazzo, Marcello Albanesi, Mattia Cristallo, et al.
Medical Sciences (Basel, Switzerland)|March 27, 2026
Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot StudyPietro Pozzessere, Mattia Di Lauro, Francesco Incantalupo, et al.
Respiratory Medicine|December 6, 2017
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year studyDanilo Di Bona, Irene Fiorino, Marialuisa Taurino, et al.
Clinical and Molecular Allergy : CMA|January 30, 2018
A 13-year real-life study on efficacy, safety and biological effects of <i>Vespula</i> venom immunotherapyMarcello Albanesi, Andrea Nico, Alessandro Sinisi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 2012
Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanomaMarcello Albanesi, David A Mancardi, Lynn E Macdonald, et al.
Respiratory Medicine|November 29, 2019
Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective studyDanilo Di Bona, Stefania Magistà, Lucia Masciopinto, et al.
European Journal of Immunology|August 22, 2014
Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastasesLeila Ben Merzoug, Solenne Marie, Naoko Satoh-Takayama, et al.
Acta Dermatovenerologica Croatica : ADC|September 6, 2017
Mast Cell Disorders, Melanoma and Pancreatic Carcinoma: From a Clinical Observation to a Brief Review of the LiteratureGiovanni Paolino, Maria Belmonte, Stefania Trasarti, et al.
The Journal of Allergy and Clinical Immunology. Global|March 4, 2026
Response to venom immunotherapy: Exploratory retrospective machine learning clustering analysisStefano Palazzo, Marcello Albanesi, Mattia Cristallo, et al.
Medical Sciences (Basel, Switzerland)|March 27, 2026
Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot StudyPietro Pozzessere, Mattia Di Lauro, Francesco Incantalupo, et al.
Respiratory Medicine|December 6, 2017
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year studyDanilo Di Bona, Irene Fiorino, Marialuisa Taurino, et al.
Clinical and Molecular Allergy : CMA|January 30, 2018
A 13-year real-life study on efficacy, safety and biological effects of <i>Vespula</i> venom immunotherapyMarcello Albanesi, Andrea Nico, Alessandro Sinisi, et al.
Pageof 3